About Royalty Pharma
Royalty Pharma is a company based in New York (United States) founded in 1996 by Rory Riggs and Pablo Legorreta. The company has 99 employees as of December 31, 2024. Royalty Pharma has completed 4 acquisitions, including Cypress Bioscience, Emgality and Minerva Neurosciences. Royalty Pharma offers products and services including Royalty Acquisitions and Funding Solutions.
- Headquarter New York, United States
- Employees 99 as on 31 Dec, 2024
- Founders Rory Riggs, Pablo Legorreta
- Stage Public
-
Sectors
Financial Services
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Royalty Pharma Plc
-
Annual Revenue
$2.26 B (USD)-3.86as on Dec 31, 2024
-
Net Profit
$858.98 M (USD)-24.31as on Dec 31, 2024
-
EBITDA
$1.29 B (USD)-13.38as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
99
as on Dec 31, 2024
-
Investments & Acquisitions
Cypress Bioscience
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Royalty Pharma
Royalty Pharma is a publicly listed company on the NASDAQ with ticker symbol RPRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Royalty Pharma
Royalty Pharma offers a comprehensive portfolio of products and services, including Royalty Acquisitions and Funding Solutions.
Biopharmaceutical royalties are acquired by Royalty Pharma to support funding in life sciences
Tailored funding solutions are provided by Royalty Pharma for innovation in biotechnology and pharmaceuticals
People of Royalty Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Royalty Pharma
Investors in Royalty Pharma
Royalty Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include General Atlantic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Locked | Locked | Locked |
Investor details for Royalty Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Royalty Pharma
Royalty Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cypress Bioscience, Emgality and Minerva Neurosciences.
Investment portfolio details for Royalty Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Patient healthcare services are provided to support individual well-being.
|
Locked | Locked | 2016 | Locked | |
|
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Locked | Locked | 2010 | Locked | |
|
Developing drugs against Psychiatric and other CNS Diseases
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Royalty Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Royalty Pharma
Detailed financials for Royalty Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Royalty Pharma Comparisons
Peer comparison for Royalty Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Royalty Pharma
Detailed competitors of Royalty Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Royalty Pharma
Complete news archive for Royalty Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Royalty Pharma
Royalty Pharma was founded in 1996 and raised its 1st funding round 24 years after it was founded.
Royalty Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Pablo Legorreta is the current CEO of Royalty Pharma. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Royalty Pharma is 99.
Annual revenue of Royalty Pharma is $2.26B as on Dec 31, 2024.
Royalty Pharma was founded in 1996 in New York, United States, and operates as a private equity firm focused on biopharmaceutical investments. Royalties and stakes in marketed and late-stage products are acquired to support development and commercialization. In 2022, annual revenues of 2.24 billion were achieved, with net profit at 0.04 billion. Operations span global biopharma sectors, led by executives including co-founders Pablo Legorreta and Rory Riggs.
Royalty Pharma offers Royalty Acquisitions and Funding Solutions.
Yes, Royalty Pharma is publicly traded on NASDAQ under the ticker symbol RPRX.
Royalty Pharma has made 4 acquisitions, including Cypress Bioscience, Emgality, and Minerva Neurosciences.
Royalty Pharma has 1 investor. Key investors include General Atlantic.
The ticker symbol of Royalty Pharma is RPRX on NASDAQ.